Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Phathom Pharmaceuticals (NASDAQ: PHAT) announced the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, along with associated inducement awards. The Board granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the remainder vesting in 36 monthly installments. Additionally, Bentley received 57,143 restricted stock units vesting in three equal annual installments and 50,000 restricted stock units vesting in two equal annual installments.
Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and DUAL PAK® for H. pylori infection treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT) ha annunciato la nomina di Jonathan Bentley come Senior Vice President, Responsabile delle Vendite, insieme a premi di incentivazione correlati. Il Consiglio ha concesso a Bentley un'opzione azionaria non qualificata per l'acquisto di 79.365 azioni ordinarie, con il 25% che matura il 1° maggio 2026 e il resto che matura in 36 rate mensili. Inoltre, Bentley ha ricevuto 57.143 unità azionarie vincolate che maturano in tre rate annuali uguali e 50.000 unità azionarie vincolate che maturano in due rate annuali uguali.
Phathom è specializzata in trattamenti per le malattie gastrointestinali e commercializza VOQUEZNA® per il trattamento del bruciore di stomaco e del GERD, insieme a VOQUEZNA® TRIPLE PAK® e DUAL PAK® per il trattamento dell'infezione da H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT) anunció el nombramiento de Jonathan Bentley como Vicepresidente Senior y Jefe de Ventas, junto con premios de incentivo asociados. La Junta otorgó a Bentley una opción sobre acciones no calificadas para comprar 79,365 acciones ordinarias, con un 25% que se consolidará el 1 de mayo de 2026, y el resto se consolidará en 36 cuotas mensuales. Además, Bentley recibió 57,143 unidades restringidas de acciones que se consolidan en tres cuotas anuales iguales y 50,000 unidades restringidas de acciones que se consolidan en dos cuotas anuales iguales.
Phathom se especializa en tratamientos para enfermedades gastrointestinales y comercializa VOQUEZNA® para el tratamiento de la acidez y el reflujo gastroesofágico (GERD), junto con VOQUEZNA® TRIPLE PAK® y DUAL PAK® para el tratamiento de la infección por H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT)는 Jonathan Bentley를 수석 부사장 겸 영업 책임자로 임명했으며, 이에 따른 인센티브 보상을 발표했습니다. 이사회는 Bentley에게 79,365주의 보통주를 매수할 수 있는 비자격 주식 옵션을 부여했으며, 25%는 2026년 5월 1일에 권리가 발생하고 나머지는 36개월에 걸쳐 매월 분할하여 권리가 발생합니다. 또한 Bentley는 57,143 제한 주식 단위를 3년에 걸쳐 매년 동일한 비율로 취득하며, 50,000 제한 주식 단위는 2년에 걸쳐 매년 동일한 비율로 취득합니다.
Phathom은 위장 질환 치료에 특화되어 있으며, 속쓰림과 위식도 역류질환(GERD) 치료제인 VOQUEZNA®와 H. pylori 감염 치료를 위한 VOQUEZNA® TRIPLE PAK® 및 DUAL PAK®를 판매하고 있습니다.
Phathom Pharmaceuticals (NASDAQ: PHAT) a annoncé la nomination de Jonathan Bentley en tant que Senior Vice President, Responsable des Ventes, accompagnée de primes incitatives associées. Le conseil d'administration a accordé à Bentley une option d'achat d'actions non qualifiée pour acquérir 79 365 actions ordinaires, dont 25 % deviendront acquises le 1er mai 2026, le reste étant acquis en 36 versements mensuels. De plus, Bentley a reçu 57 143 unités d'actions restreintes acquises en trois versements annuels égaux et 50 000 unités d'actions restreintes acquises en deux versements annuels égaux.
Phathom est spécialisée dans les traitements des maladies gastro-intestinales et commercialise VOQUEZNA® pour le traitement des brûlures d'estomac et du RGO, ainsi que VOQUEZNA® TRIPLE PAK® et DUAL PAK® pour le traitement de l'infection à H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT) gab die Ernennung von Jonathan Bentley zum Senior Vice President und Vertriebsleiter bekannt, zusammen mit damit verbundenen Anreizprämien. Der Vorstand gewährte Bentley eine nicht qualifizierte Aktienoption zum Kauf von 79.365 Aktien des Stammkapitals, wobei 25 % am 1. Mai 2026 unverfallbar werden und der Rest in 36 monatlichen Raten. Zusätzlich erhielt Bentley 57.143 Restricted Stock Units, die in drei gleichen jährlichen Raten unverfallbar werden, sowie 50.000 Restricted Stock Units, die in zwei gleichen jährlichen Raten unverfallbar werden.
Phathom ist auf die Behandlung von Magen-Darm-Erkrankungen spezialisiert und vertreibt VOQUEZNA® zur Behandlung von Sodbrennen und GERD sowie VOQUEZNA® TRIPLE PAK® und DUAL PAK® zur Behandlung von H.-pylori-Infektionen.
- None.
- None.
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company’s Board of Directors has approved the grant of inducement awards.
On May 1, 2025, the Company’s Board of Directors granted inducement awards to Mr. Bentley under the Company’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common stock under the Inducement Plan,
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
Who is the new SVP Head of Sales at Phathom Pharmaceuticals (PHAT)?
What stock options were granted to Jonathan Bentley at Phathom Pharmaceuticals?
How many restricted stock units (RSUs) did Phathom Pharmaceuticals grant to Jonathan Bentley?
What products does Phathom Pharmaceuticals (PHAT) currently market?
